Teva, AbbVie To Face Trial Over Niaspan Pay-For-Delay Claims
Long-running multidistrict litigation over AbbVie and Teva Pharmaceuticals' agreement to delay generic forms of cholesterol drug Niaspan is headed toward trial, after a Pennsylvania federal judge Friday found a genuine dispute...To view the full article, register now.
Already a subscriber? Click here to view full article